Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop IRD Treatment

July 9, 2020

Massachusetts Eye and Ear is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common cause for autosomal dominant retinitis pigmentosa.

Previous lab-based research performed by members of the Harvard Ophthalmology Ocular Genomics Institute, led by Eric A. Pierce, MD, PhD, the William F. Chatlos Professor of Ophthalmology at Harvard Medical School, demonstrated that adeno-associated, virus-mediated gene augmentation therapy for PRPF31 can restore normal function to PRPF31 mutant RPE cells. Biogen will build upon this prior work and conduct the studies needed for clinical development of PRPF31 gene therapy. Read the press release